Trastuzumab and cardiotoxicity: Weighing the risks

American Journal of Health-System Pharmacy

Volumn 63, Issue 6, 2006, Pages 525-

  Wong, Siu Fun ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; SURVIVAL;

EID: 33645064522     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050549     Document Type: Editorial

References (6)

1. Romond EH, Perez E, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-84.
2. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23:7811-9.
3. Piccart-Gebhart M, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1650-72.
4. Slamon D, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92.
5. Ewer M, Vooletich M, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23:7820-6.
6. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. www.abstracts2view.com/sabcs05/ view.php?nu=SABCS05L_921 (accessed 2006 Feb 1).